HOME >> MEDICINE >> NEWS
Therapy for mice with prion disease could offer benefit to human beings with CJD

Authors of a fast-track research letter in this week's issue of THE LANCET describe a therapeutic treatment which increased the survival time for mice with prion disease. These results could represent a new approach to treating CJD in human beings.

The lack of an immune response to prions--the infectious proteins that cause scrapie, bovine spongiform encephalopathy (BSE), and Creutzfeldt-Jakob disease (CJD)--might be related to the fact that these agents do not contain nucleic acids (genetic material).

Hans Kretzschmar from Ludwig-Maximilians University and colleagues from the Technical University Munich, Germany, and Coley Pharmaceuticals, aimed to use genetic material (a specific type of nucleotide arrangement called CpG oligodeoxynucleotides) as a form of disease treatment after prion infection in mice. CpG oligodeoxynucleotides have previously been shown to stimulate the immune response.

The investigators inoculated 24 healthy mice with brain extracts from mice infected with scrapie prions, and then injected CpG oligodeoxynucleotides. This procedure resulted in 38% longer survival times than a control group that were injected with saline solution; longer survival times occurred when CpG oligodeoxynucleotides were given repeatedly over a three-week period.

Hans Kretzschmar comments: "The most likely explanation is the stimulation of TLR9-expressing cells of the innate immune system such as macrophages, monocytes, and dendritic cells. CpG oligodeoxynucleotides have not been shown to have adverse effects to human health and could therefore be considered as a therapeutic choice after prion infection."

In an accompanying Commentary (p 184), George Carlson from the McLaughlin Research Institute, USA, states that the approach of Kretzschmar and colleagues is reasonable, and concludes: "Development of improved diagnostics and postexposure prophylaxis are urgently needed given the unknown prevalence of subclinical prion infecti
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
18-Jul-2002


Page: 1 2

Related medicine news :

1. UT Southwestern Moncrief Cancer Center is first in Texas to treat patients with TomoTherapy
2. Therapy, medication combination superior for children with obsessive-compulsive disorder
3. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
4. Vagus Nerve Stimulation Therapy (TM) more effective in epilepsy patients when used earlier
5. Therapy to help women reduce their concerns about gaining weight found to be effective in helping them to stop smoking
6. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
7. UCSF Study Shows That An Herbal Therapy Reduces PSA Levels By Half In Men With Advanced Prostate Cancer
8. Sniffing Out The Promise Of Anti-Angiogenesis Therapy
9. Breakthrough New Therapy Uses Antibody-Targeted Chemotherapy To Fight Leukemia
10. Jefferson Researchers Report First Evidence Of Radiation Therapy Preventing Prostate Cancer Patients From Dying
11. Combination Therapy Improves Chances Of Surviving Esophageal Cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
(Date:6/24/2016)... ... 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona has re-located to ... vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new retreat center ... as well as the Sedona Rouge, both popular accommodations for SpiritQuest clients. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
Cached News: